All In Biotech

Drug Trial Radar · NCT00238732

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

A Double-Blind, Randomized, Placebo-and Active-Controlled Efficacy and Safety Study of Bazedoxifene/Conjugated Estrogens Combinations for Treatment of Moderate to Severe Vulvar/Vaginal Atrophy in Postmenopausal Women

Last checked: Nov 20, 2026Latest source record: Dec 28, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

650

Actual

Start

Oct 2005

Primary completion

Not stated

Study completion Mar 2007

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Diagnostic
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.

Conditions

  • Vaginal Atrophy

Interventions

  • Bazedoxifene/Conjugated EstrogenDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Superficial cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
  2. Parabasal cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.

Locations

63 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Montgomery, Alabama

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Oakland, California

  • Site not named

    San Diego, California

  • Site not named

    Upland, California

  • Site not named

    Denver, Colorado

  • Site not named

    Avon, Connecticut

  • Site not named

    Groton, Connecticut

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Aventura, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Palm Harbor, Florida

  • Site not named

    Palm Springs, Florida

  • Site not named

    Pinnellas Park, Florida

  • Site not named

    Stuart, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Conyers, Georgia

  • Site not named

    Douglasville, Georgia

  • Site not named

    Savannah, Georgia

  • Site not named

    Idaho Falls, Idaho

  • Site not named

    Champaign, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Kansas City, Kansas

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Booklyn Center, Minnesota

  • Site not named

    Chaska, Minnesota

  • Site not named

    Jackson, Mississippi

  • Site not named

    Kansas, Mississippi

  • Site not named

    Creve Cour, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Lebanon, New Hampshire

  • Site not named

    Livingston, New Jersey

  • Site not named

    New Brunswick, New Jersey

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.